FDA Approves First Generic Versions of FARXIGA - Takeaway - MDSpire
FDA & Government News

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Share

  • 1

    FDA approves first generic dapagliflozin for type 2 diabetes.

  • 2

    Helps reduce hospitalization risks for heart failure.

  • 3

    Acts as a sodium-glucose cotransporter 2 inhibitor.

  • 4

    Safety concerns include diabetic ketoacidosis and infections.

  • 5

    Over 40 million Americans affected by diabetes.

  • 6

    Physicians should refer to the Orange Book for product details.

  • 7

    Contraindicated in patients with serious hypersensitivity to dapagliflozin.

  • 8

    Adverse events include female genital infections and urinary tract infections.

Original Source(s)

FDA Approves First Generic Versions of FARXIGA

  • by Kathryn Wighton

  • April 7, 2026

Related Content

The Missing Piece in the Dark Metabolome Puzzle?

Microdroplets formed during electrospray ionization may trigger chemical reactions that help explain a substantial portion of the “dark metabolome” – though some researchers question their relevance under typical metabolomics conditions

Wegovy and Possible Vision Risk

Higher dose weight loss injectable demonstrates nearly five times higher ischaemic optic neuropathy risk than other semaglutide GLP-1 agonists

  • April 8, 2026

  • 3 min
Deprescribing Seen in T2D Care

Researchers examine medication changes in practices with lifestyle medicine access